Methods: Pts ≥years with newly Starthour from start of methotrexate infusion. Dosemg everyhours fordoses, then everyhours until methotrexate level is less than micromol/L. Administration: Give intravenous boluses for at least the firstdoses then change to oral if the patient is compliant and not vomiting Patients ≥years of age who are diagnosed with T cell ALL are treated similarly to younger patients with a com-bination of hyperCVAD, nelarabine, and asparaginase. The age-adjusted hyperCVAD and a lower pegaspar-gase dosage (IU/m2; maximum IU) is used for these patients (Table 2) Short NJ, Kantarjian H, Ravandi F. Updated results of a phase II study of reduced-intensity chemotherapy with mini-hyper-CVD in combination with inotuzumab ozogamicin, with or without blinatumomab, in older adults with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia In a phase II study evaluating mini-hyper-CVD (a lower intensity version of the hyper-CVAD regimen without anthracycline) in combination with inotuzumab ozogamicin with or without blinatumomab in patients agedyears or older, the MRD negativity rates were% at CR and% overall To further improve outcomes in patients with R/R B cell ALL and reduce toxicity, inotuzumab and blinatumomab have been strategically incorporated into a mini-hyperCVD (mini-HCVD) chemotherapy backbone The hyperCVAD combination alternating with high-dose methotrexate (MTX) and cytarabine for a total ofintensive courses was first described in The initial In a phase II study evaluating mini-hyper-CVD (a lower intensity version of the hyper-CVAD regimen without anthracycline) in combination with inotuzumab ozogamicin with Without an overactive kinase to target, multiple trials of “traditional” chemotherapy designed specifi cally for older adults were undertaken with disappointing results: persistent high Mini-HCVD (cyclophosphamide and dexamethasone at% dose reduction, no anthracycline, methotrexate at% dose reduction, cytarabine at g/m2 fordoses) Aims: To evaluate the combination of low-intensity chemotherapy and INO with or without Blina, in older pts with newly diagnosed B-ALL.
Methods: Pts ≥years with newly Starthour from start of methotrexate infusion. Dosemg everyhours fordoses, then everyhours until methotrexate level is less than micromol/L. Administration: Give intravenous boluses for at least the firstdoses then change to oral if the patient is compliant and not vomiting Patients ≥years of age who are diagnosed with T cell ALL are treated similarly to younger patients with a com-bination of hyperCVAD, nelarabine, and asparaginase. The age-adjusted hyperCVAD and a lower pegaspar-gase dosage (IU/m2; maximum IU) is used for these patients (Table 2) Short NJ, Kantarjian H, Ravandi F. Updated results of a phase II study of reduced-intensity chemotherapy with mini-hyper-CVD in combination with inotuzumab ozogamicin, with or without blinatumomab, in older adults with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia In a phase II study evaluating mini-hyper-CVD (a lower intensity version of the hyper-CVAD regimen without anthracycline) in combination with inotuzumab ozogamicin with or without blinatumomab in patients agedyears or older, the MRD negativity rates were% at CR and% overall To further improve outcomes in patients with R/R B cell ALL and reduce toxicity, inotuzumab and blinatumomab have been strategically incorporated into a mini-hyperCVD (mini-HCVD) chemotherapy backbone The hyperCVAD combination alternating with high-dose methotrexate (MTX) and cytarabine for a total ofintensive courses was first described in The initial In a phase II study evaluating mini-hyper-CVD (a lower intensity version of the hyper-CVAD regimen without anthracycline) in combination with inotuzumab ozogamicin with Without an overactive kinase to target, multiple trials of “traditional” chemotherapy designed specifi cally for older adults were undertaken with disappointing results: persistent high Mini-HCVD (cyclophosphamide and dexamethasone at% dose reduction, no anthracycline, methotrexate at% dose reduction, cytarabine at g/m2 fordoses) Aims: To evaluate the combination of low-intensity chemotherapy and INO with or without Blina, in older pts with newly diagnosed B-ALL.
Français
English
Deutsch
Español
Italiano
Português